Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Large B-Cell, Diffuse 2Waldenstrom Macroglobulinemia 1Lymphoma, Mantle-Cell 1Lymphoma, Follicular 1Lymphoma, B-Cell 1Lymphoma 1

Interventions

Lenalidomide 11Cyclophosphamide 11Rituximab 10Prednisone 8Magnetic Resonance Spectroscopy 7obinutuzumab 6Vincristine 6Doxorubicin 6Specimen Handling 5Biopsy 5Bendamustine Hydrochloride 5fludarabine phosphate 3fludarabine 3Whole-Body Irradiation 3Radiotherapy 3R-CHOP protocol 3Cyclosporine 3zanubrutinib 2tazemetostat 2pembrolizumab 2ibrutinib 2Temozolomide 2Prednisolone 2Peripheral Blood Stem Cell Transplantation 2Oxaliplatin 2Mycophenolic Acid 2Melphalan 2Gemcitabine 2Etoposide 2Dexamethasone 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma, Follicular × loncastuximab tesirine × 30 days × Clear all
NCT05453396 2026-05-11

Loncastuximab Tesirine for the Treatment of Relapsed or Refractory B-Cell Malignancies

University of Washington

Phase 2 Recruiting
20 enrolled
Lymphoid

Lymphoma, Follicular, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡